Author

J. Paynter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:CRISPR screen· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

J. Zhu· 2 shared L. He· 2 shared Y.-N. Zhang· 2 shared A. Antanasijevic· 1 shared A. Civitarese· 1 shared A. E. Goodroe· 1 shared A. Hatzipantelis· 1 shared A. Ward· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

J. Zhu

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimers as HIV-1 vaccine candidates

Y.-N. Zhang, J. Paynter, A. Antanasijevic, J. D. Allen, M. Eldad, Y.-Z. Lee, J. Copps, M. Newby, L. He, D. Chavez, P. Frost, A. E. Goodroe, J. W. Dutton, R. Lanford, C. Chen, , J. Zhu

Glycan trimming of HIV-1 Env immunogens improves vaccine-induced neutralizing antibody responses in small animals and primates.

bioRxiv · Jul 1, 2022Microbiology

CRISPR screens identify gene targets and drug repositioning opportunities at breast cancer risk loci

N. K. Tuano, J. Beesley, M. Manning, W. Shi, L. Malver-Ortega, J. Paynter, D. Black, A. Civitarese, K. McCue, A. Hatzipantelis, K. Hillman, S. Kaufmann, H. Sivakumaran, J. M. Polo, R. Reddel, , J. Rosenbluh

bioRxiv · Sep 7, 2021 · PreprintCancer Biology

Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants

Y.-N. Zhang, J. Paynter, C. Sou, T. Fourfouris, Y. Wang, C. Abraham, T. Ngo, Y. Zhang, L. He, J. Zhu

A nanoparticle vaccine candidate induces broadly neutralizing antibodies against multiple SARS-CoV-2 variants through enhanced immune responses.

bioRxiv · Mar 26, 2021Immunology